Novartis
NVS
987 hedge funds and large institutions have $19.3B invested in Novartis in 2018 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 343 increasing their positions, 397 reducing their positions, and 82 closing their positions.
261% more call options, than puts
Call options by funds: $96.7M | Put options by funds: $26.8M
0.28% more ownership
Funds ownership: 10.91% → 11.19% (+0.28%)
3% less funds holding
Funds holding: 1,013 → 987 (-26)
7% less capital invested
Capital invested by funds: $20.7B → $19.3B (-$1.35B)
14% less repeat investments, than reductions
Existing positions increased: 343 | Existing positions reduced: 397
21% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 82
46% less funds holding in top 10
Funds holding in top 10: 24 → 13 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSIA
Charles Schwab Investment Advisory
San Francisco,
California
|
+$303M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$222M |
| 3 |
Renaissance Technologies
New York
|
+$140M |
| 4 |
D.E. Shaw & Co
New York
|
+$79M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$76.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parnassus Investments
San Francisco,
California
|
-$373M |
| 2 |
BBHC
Brown Brothers Harriman & Co
New York
|
-$67.1M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$65.6M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$45.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.5M |
NVS Hedge Fund Activity: Q2 2018 in Review
987 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2018, worth a combined $19.3B — down 6.5% from $20.7B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of NVS and 65 opened new positions — a net loss of 17 holders — while 397 trimmed existing stakes and 343 added.
The largest buyer was Charles Schwab Investment Advisory, opening a new position worth an estimated $303M. The largest seller was Parnassus Investments, cutting an estimated $373M.
- 987 institutional investors held Novartis (NVS) as of Q2 2018, down from 1,013 in Q1 2018.
- Funds reported $19.3B of Novartis stock for Q2 2018, down 6.5% quarter-over-quarter.
- 65 funds opened new Novartis positions in Q2 2018 and 82 closed out, a net change of -17 holders.
- The largest Novartis buyer in Q2 2018 was Charles Schwab Investment Advisory, an estimated $303M added.
- The largest Novartis seller in Q2 2018 was Parnassus Investments, an estimated $373M sold.
Based on aggregated 13F filings for Q2 2018.